This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

RNA Leaders USA
New Data, Case Studies & Partners
September 4th-5th, 2024San Diego Convention Center, USA



A new era of RNA biotherapeutics is here - but the platform has significant limitations with fragile, costly liquid drug products needing injection. Ziccum's unique LaminarPace technology can help unleash the full RNA potential. Thanks to a very gentle treatment based on a unique mass transfer principle, LaminarPace transforms delicate liquid biologics into robust, thermostable, dry powders while preserving the RNA activity and offering particle engineering possibilities. Discover LaminarPace, its solid, validated data for mRNA/LNP and the possibilities this disruptive but yet cost-efficient technology can bring to your next-generation biotherapeutics with Ziccum CEO Ann Gidner.

We're bringing you

  • Enabling The Full Potential Of mRNA – With Robust, Particle Engineered, Thermostable Dry Product Forms